Table 1

Demographic and clinical characteristics of the enrolled participants

CharacteristicsHCWsPwMSP value
Total, N (%)40 (100)22 (100)
Age, years (IQR)43 (29–51)51 (47–58)0.0013*
Male, N (%)11 (27.5)5 (22.72)0.681†
Origin
 Western Europe39220.445†
 Asia10
BMI kg/m2 23.90
Treatment duration, years (IQR)5.26 (2.1–9.2)
Time to last relapse, y (IQR)6.5 (2.4–10.3)
CD4:CD8 T cell ratio‡2.1 (0.8–3.4)1.9 (1.1–2.6)0.842*
MS treatment
 Ocrelizumab, N (%)5 (22.72)
 Fingolimod, N (%)9 (40.9)
 Cladribine, N (%)3 (13.63)
 IFN-β, N (%)5 (22.72)
  • *Mann-Whitney U statistic test.

  • †χ2 test

  • ‡CD4:CD8 T cell ratio is a marker of immune-senescence.26

  • BMI, body mass index; HCWs, healthcare workers; IFN-β, interferon beta; N, Number; PwMS, patients with multiple sclerosis.